BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37889120)

  • 1. Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.
    Goetz MP; Hamilton EP; Campone M; Hurvitz SA; Cortes J; Johnston S; Llombart-Cussac A; Kaufman PA; Toi M; Jerusalem G; Graham H; Wang H; Jansen VM; Litchfield LM; Martin M
    Clin Cancer Res; 2024 May; 30(10):2233-2244. PubMed ID: 37889120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
    Goetz MP; Martin M; Tokunaga E; Park IH; Huober J; Toi M; Stoffregen C; Shekarriz S; Andre V; Gainford MC; Price GL; Johnston S
    Oncologist; 2020 Sep; 25(9):e1346-e1354. PubMed ID: 32536013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
    Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
    J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.
    Jiang H; Zhong J; Wang J; Song G; Di L; Shao B; Zhang R; Liu Y; Zhu A; Wang N; Li H
    Cancer Med; 2024 May; 13(10):e7249. PubMed ID: 38770648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
    Tolaney SM; Toi M; Neven P; Sohn J; Grischke EM; Llombart-Cussac A; Soliman H; Wang H; Wijayawardana S; Jansen VM; Litchfield LM; Sledge GW
    Clin Cancer Res; 2022 Apr; 28(8):1500-1506. PubMed ID: 35121623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
    Goetz MP; Toi M; Campone M; Sohn J; Paluch-Shimon S; Huober J; Park IH; Trédan O; Chen SC; Manso L; Freedman OC; Garnica Jaliffe G; Forrester T; Frenzel M; Barriga S; Smith IC; Bourayou N; Di Leo A
    J Clin Oncol; 2017 Nov; 35(32):3638-3646. PubMed ID: 28968163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
    Toi M; Inoue K; Masuda N; Iwata H; Sohn J; Hae Park I; Im SA; Chen SC; Enatsu S; Turner PK; André VAM; Hardebeck MC; Sakaguchi S; Goetz MP; Sledge GW
    Cancer Sci; 2021 Jun; 112(6):2381-2392. PubMed ID: 33686753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
    Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project.
    Hattori M; Serelli-Lee V; Naito Y; Yamanaka T; Yasojima H; Nakamura R; Fujisawa T; Imai M; Nakamura Y; Bando H; Kawaguchi T; Yoshino T; Iwata H
    JCO Precis Oncol; 2024 Apr; 8():e2300647. PubMed ID: 38635933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR
    Dickler MN; Tolaney SM; Rugo HS; Cortés J; Diéras V; Patt D; Wildiers H; Hudis CA; O'Shaughnessy J; Zamora E; Yardley DA; Frenzel M; Koustenis A; Baselga J
    Clin Cancer Res; 2017 Sep; 23(17):5218-5224. PubMed ID: 28533223
    [No Abstract]   [Full Text] [Related]  

  • 13. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
    Sammons S; Shastry M; Dent S; Anders C; Hamilton E
    Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.
    Bardia A; Su F; Solovieff N; Im SA; Sohn J; Lee KS; Campos-Gomez S; Jung KH; Colleoni M; Vázquez RV; Franke F; Hurvitz S; Harbeck N; Chow L; Taran T; Rodriguez Lorenc K; Babbar N; Tripathy D; Lu YS
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34504990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.
    Corona SP; Generali D
    Drug Des Devel Ther; 2018; 12():321-330. PubMed ID: 29497278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.
    Goetz MP; Toi M; Huober J; Sohn J; Trédan O; Park IH; Campone M; Chen SC; Manso LM; Paluch-Shimon S; Freedman OC; O'Shaughnessy J; Pivot X; Tolaney SM; Hurvitz SA; Llombart-Cussac A; André V; Saha A; van Hal G; Shahir A; Iwata H; Johnston SRD
    Ann Oncol; 2024 May; ():. PubMed ID: 38729566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
    Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Conte P; Lu Y; Barriga S; Hurt K; Frenzel M; Johnston S; Llombart-Cussac A
    JAMA Oncol; 2020 Jan; 6(1):116-124. PubMed ID: 31563959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2- advanced breast cancer.
    Hong J; Chen T; Ouyang L; Du N; Li A; Zhou Z; Zhang H; Xia Z; Meng J
    Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):559-566. PubMed ID: 38470447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
    Palumbo A; Lau G; Saraceni M
    Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.